Portside Wealth Group LLC Takes Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Portside Wealth Group LLC purchased a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 5,352 shares of the medical instruments supplier's stock, valued at approximately $497,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Norden Group LLC bought a new stake in LeMaitre Vascular during the 1st quarter worth about $401,000. BNP Paribas Financial Markets increased its holdings in shares of LeMaitre Vascular by 135.6% in the first quarter. BNP Paribas Financial Markets now owns 22,917 shares of the medical instruments supplier's stock valued at $1,521,000 after purchasing an additional 13,189 shares in the last quarter. Texas Permanent School Fund Corp raised its position in LeMaitre Vascular by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier's stock worth $1,151,000 after purchasing an additional 225 shares during the last quarter. Envestnet Portfolio Solutions Inc. acquired a new position in LeMaitre Vascular during the 1st quarter worth $206,000. Finally, Quantbot Technologies LP boosted its position in LeMaitre Vascular by 1,001.4% in the 1st quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier's stock valued at $487,000 after buying an additional 6,669 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LMAT has been the subject of a number of recent research reports. StockNews.com upgraded LeMaitre Vascular from a "hold" rating to a "buy" rating in a research report on Wednesday. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They issued a "buy" rating and a $105.00 target price on the stock. Oppenheimer reissued an "outperform" rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. JMP Securities raised their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a "market outperform" rating in a research note on Tuesday, August 20th. Finally, Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They set a "neutral" rating and a $96.00 target price for the company. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, LeMaitre Vascular currently has an average rating of "Moderate Buy" and a consensus price target of $94.57.

Insiders Place Their Bets

In related news, Director David B. Roberts sold 3,063 shares of the business's stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now directly owns 14,114 shares of the company's stock, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 10.79% of the company's stock.

LeMaitre Vascular Price Performance

LMAT traded up $3.18 during mid-day trading on Friday, hitting $104.25. The stock had a trading volume of 178,721 shares, compared to its average volume of 134,146. The stock's fifty day simple moving average is $90.66 and its 200-day simple moving average is $84.41. The firm has a market capitalization of $2.34 billion, a price-to-earnings ratio of 56.97, a price-to-earnings-growth ratio of 2.49 and a beta of 0.89. LeMaitre Vascular, Inc. has a 1-year low of $47.72 and a 1-year high of $104.81.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. During the same quarter last year, the business posted $0.33 EPS. The firm's revenue was up 15.6% compared to the same quarter last year. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a yield of 0.61%. LeMaitre Vascular's payout ratio is 34.97%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.